REXAHN PHARMACEUTICALS, INC. 4

Accession 0000893838-06-000055

$IRDCIK 0001228627operating

View on SEC.gov Company Profile

Filed

May 2, 8:00 PM ET

Accepted

May 3, 9:08 PM ET

Size

27.3 KB

Accession

0000893838-06-000055

Insider Transaction Report

Form 4

Period: 2005-09-12

REXAHN PHARMACEUTICALS, INC.RXHN

HOLADAY JOHN W DR

Director

Transactions

Award
Stock option (right ot buy)
2006-05-01+125,000→ 125,000 total
Exercise: $0.80Exp: 2016-05-02→ Common stock (125,000 underlying)
Award
Stock option (right ot buy)
2006-05-01+70,000→ 70,000 total
Exercise: $0.80Exp: 2016-05-02→ Common stock (70,000 underlying)
Disposition to Issuer
Stock option (right ot buy)
2006-05-01−70,000→ 0 total
Exercise: $0.80Exp: 2016-05-02→ Common stock (70,000 underlying)
Disposition to Issuer
Stock option (right ot buy)
2006-05-01−125,000→ 0 total
Exercise: $0.80Exp: 2016-05-02→ Common stock (125,000 underlying)
Award
Stock option (right ot buy)
2005-12-08+70,000→ 70,000 total
Exercise: $0.80Exp: 2013-08-05→ Common stock (70,000 underlying)
Award
Stock option (right ot buy)
2005-12-08+125,000→ 125,000 total
Exercise: $0.80Exp: 2014-04-20→ Common stock (125,000 underlying)
Award
Stock option (right ot buy)
2006-05-01+20,000→ 20,000 total
Exercise: $3.00Exp: 2016-05-02→ Common stock (20,000 underlying)
Disposition to Issuer
Stock option (right ot buy)
2005-12-08−125,000→ 0 total
Exercise: $0.24Exp: 2014-04-20→ Common stock (125,000 underlying)
Disposition to Issuer
Stock option (right ot buy)
2005-12-08−70,000→ 30,000 total
Exercise: $0.24Exp: 2013-08-05→ Common stock (100,000 underlying)
Award
Stock option (right ot buy)
2005-09-12+20,000→ 20,000 total
Exercise: $3.00From: 2006-09-12Exp: 2015-09-12→ Common stock (20,000 underlying)
Disposition to Issuer
Stock option (right ot buy)
2006-05-01−20,000→ 0 total
Exercise: $3.00Exp: 2016-05-02→ Common stock (20,000 underlying)

Footnotes (6)

[F1]As of August 5, 2005, 60% of the options were vested; the remaining 40% of the options vest and become exercisable on August 5, 2006.
[F2]The transaction involved an amendment of outstanding options to change the exercise price with respect to 70,000 options from $0.24 to $0.80, resulting in the deemed cancellation of a portion of the original options and the grant of replacement options with the same vesting and exercisability terms as the cancelled options.
[F3]As of April 20, 2006, 60% of the options were vested; the remaining 40% of the options vest and become exercisable on April 20, 2007.
[F4]The transaction involved an amendment of outstanding options to change the exercise price with respect to 125,000 options from $0.24 to $0.80, resulting in the deemed cancellation of the original options and the grant of replacement options with the same vesting and exercisability terms as the cancelled options.
[F5]Pursuant to an agreement dated May 2, 2006, all of Dr. Holaday's options vest and become exercisable immediately upon his termination of service as director of Rexahn Pharmaceuticals, Inc. and may be exercised until 10 years after the original date of grant.
[F6]The transaction involved an amendment of outstanding options to accelerate vesting and extend the exercise period pursuant to an agreement dated May 2, 2006, resulting in the deemed cancellation of the original options and the grant of replacement options with the same vesting and exercisability terms as the cancelled options.

Documents

1 file

4
rexform4holaday_ex.xmlPrimary

Issuer

REXAHN PHARMACEUTICALS, INC.

CIK 0001228627

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0001228627

Filing Metadata

Form type: 4
Filed: May 2, 8:00 PM ET
Accepted: May 3, 9:08 PM ET
Size: 27.3 KB

View on SEC.gov